DHEA — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
26 expert mentions
"If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels."
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
"I do measure DHEA-S — the sulfated form — in patients over 50."
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
The expert's claim is a clinical practice recommendation about measuring DHEA-S levels in patients over 50, which is a diagnostic/monitoring approach rather than a therapeutic intervention. None of the 10 provided studies directly address the clinical utility or guideline support for routine DHEA-S measurement in adults over 50. The most relevant study (PMID: 36121077, a review of DHEA pharmacological effects) could theoretically inform the rationale for monitoring, but no key findings were extractable from the provided data. The remaining studies cover unrelated topics such as ashwagandha, IVF supplements, sarcopenia, and vitamin C, none of which bear on this specific diagnostic practice.
"If levels are very low, I'll sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels."
If DHEA-S levels are very low in patients over 50, Attia will sometimes trial DHEA at 25 to 50 milligrams per day, monitoring downstream hormones, PSA in men, and lipid panels.
None of the 10 provided studies directly evaluate the clinical protocol described by Attia — specifically, trialing DHEA at 25–50 mg/day in individuals over 50 with low DHEA-S levels while monitoring downstream hormones, PSA, and lipid panels. The DHEA pharmacology review (PMID 36121077) is the closest relevant citation, but no key findings, populations, or limitations are populated for any study, making direct evidence assessment impossible. The remaining studies address unrelated topics (ashwagandha, IVF, vitamin C, sarcopenia, 7-keto-DHEA) and do not speak to Attia's specific monitoring-based DHEA supplementation approach.
"I do measure DHEA-S — the sulfated form — in patients over 50."
In his practice, Attia measures DHEA-S — the sulfated form — in patients over 50.
"Etienne-Emile Baulieu's DHEA-age trial showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes."
The DHEA-age trial by Baulieu showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.
None of the 10 provided studies correspond to the DHEA-AGE trial by Baulieu et al., which is the specific RCT referenced in the expert's claim. The provided literature includes general DHEA reviews (PMID 36121077), testosterone prohormone reviews, and unrelated RCTs on ashwagandha and vitamin C, none of which contain data on the specific trial outcomes cited (bone density, skin quality, libido, or primary endpoints). Without the actual source study or directly relevant evidence in the provided corpus, it is not possible to verify or contradict the claim from these references alone.
"Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance."
Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.
"Etienne-Emile Baulieu's DHEA-age trial showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes."
The DHEA-age trial by Baulieu showed modest improvements in bone density, skin quality, and libido in older adults but little effect on the primary outcomes.
"More recent work suggests the effects may be more pronounced in women than men and in those with the lowest baseline levels."
More recent research suggests DHEA's effects may be more pronounced in women than men and in those with the lowest baseline levels.
"Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance."
Epidemiological studies show that higher DHEA levels correlate with lower cardiovascular risk, less abdominal obesity, and better cognitive performance.
None of the 10 retrieved studies directly address the expert's claim about DHEA levels correlating with cardiovascular risk, abdominal obesity, or cognitive performance in epidemiological research. The closest relevant study is a general review on DHEA pharmacology and therapeutic applications (PMID: 36121077), but no key findings are reported for it in the provided data. The remaining studies cover unrelated topics such as ashwagandha, IVF supplementation, testosterone prohormones, and 7-keto-DHEA, none of which test the specific epidemiological associations claimed. Without extractable findings from the DHEA review or any epidemiological cohort data in this set, it is not possible to assess whether the evidence base supports or contradicts the claim.
"More recent work suggests the effects may be more pronounced in women than men and in those with the lowest baseline levels."
More recent research suggests DHEA's effects may be more pronounced in women than men and in those with the lowest baseline levels.
None of the 10 provided studies directly address the claim that DHEA's effects are more pronounced in women than men or in those with the lowest baseline levels. While PMID 36121077 is a review on DHEA's pharmacological effects and PMID 12943723 covers androgens in women — both potentially relevant — no key findings, populations, or specific data were reported for any study in the provided research corpus. Without extractable findings from these studies, it is impossible to assess whether the evidence supports, partially supports, or contradicts Attia's claim.
"Peak DHEA levels occur around age 25 and then decline roughly 2 to 3 percent per year, reaching about 20 to 30 percent of peak values by age 70."
DHEA levels peak around age 25 and then decline roughly 2 to 3 percent per year, reaching about 20 to 30 percent of peak values by age 70.
"In tissues expressing the appropriate enzymes, DHEA is locally converted to estradiol or testosterone — what's called intracrinology."
In tissues expressing the appropriate enzymes, DHEA is locally converted to estradiol or testosterone, a process called intracrinology.
"DHEA is produced primarily by the adrenal glands and serves as a precursor to both androgens — including testosterone — and estrogens."
DHEA is produced primarily by the adrenal glands and serves as a precursor to both androgens, including testosterone, and estrogens.
"DHEA is produced primarily by the adrenal glands and serves as a precursor to both androgens — including testosterone — and estrogens."
DHEA is produced primarily by the adrenal glands and serves as a precursor to both androgens, including testosterone, and estrogens.
The expert's claim that DHEA is produced primarily by the adrenal glands and serves as a precursor to androgens and estrogens is a well-established physiological fact in endocrinology, but the provided studies do not directly confirm or refute this mechanistic claim. The most relevant study (PMID 36121077, a review of DHEA pharmacology) and PMID 18839621 (a review on adrenopause) would likely address this claim, but no key findings are reported for either. The remaining studies focus on unrelated topics such as ashwagandha, vitamin C, sarcopenia, and IVF supplementation, and provide no extractable evidence bearing on DHEA biosynthesis or its steroidogenic role.
"Peak DHEA levels occur around age 25 and then decline roughly 2 to 3 percent per year, reaching about 20 to 30 percent of peak values by age 70."
DHEA levels peak around age 25 and then decline roughly 2 to 3 percent per year, reaching about 20 to 30 percent of peak values by age 70.
None of the 10 provided studies directly investigate the age-related decline trajectory of DHEA levels, peak age, or the specific quantitative claims (2–3% per year decline, reaching 20–30% of peak by age 70). While PMID 36121077 is a review on DHEA pharmacology and PMID 18839621 addresses adrenopause—topics that could contain relevant data—no key findings, populations, or limitations are reported for any of the studies, making it impossible to extract supporting or contradicting evidence. The claim itself is consistent with widely cited endocrinology literature on adrenal aging (adrenopause), but the provided references do not furnish direct evidence to assess it.
"DHEA — dehydroepiandrosterone — is the most abundant circulating steroid hormone in the human body"
DHEA is the most abundant circulating steroid hormone in the human body.
"In tissues expressing the appropriate enzymes, DHEA is locally converted to estradiol or testosterone — what's called intracrinology."
In tissues expressing the appropriate enzymes, DHEA is locally converted to estradiol or testosterone, a process called intracrinology.
None of the 10 provided studies directly address the intracrinology concept as described by Attia — specifically the local enzymatic conversion of DHEA to estradiol or testosterone in peripheral tissues. While PMID 36121077 (a review on DHEA pharmacology) and PMID 12943723 (a review on androgens in women) are the most topically relevant and likely discuss DHEA metabolism, no key findings or data are provided for any of the listed studies, making it impossible to assess direct evidentiary support. The claim itself is a well-established mechanistic concept in endocrinology literature (associated with Fernand Labrie's research), but the supplied evidence base cannot confirm or deny it based on the information given.
"DHEA — dehydroepiandrosterone — is the most abundant circulating steroid hormone in the human body"
DHEA is the most abundant circulating steroid hormone in the human body.
None of the 10 provided studies directly address or measure the relative abundance of DHEA among circulating steroid hormones. While PMID 36121077 is a review on DHEA's pharmacological effects and could plausibly contain this information, no key findings are reported in the provided data. The claim that DHEA is the most abundant circulating steroid hormone is a well-established physiological fact in endocrinology literature, but the specific studies provided here do not supply direct evidence to support or refute it.
"because it's a steroid precursor, there are theoretical concerns about hormone-sensitive cancers."
Because DHEA is a steroid precursor, there are theoretical concerns about hormone-sensitive cancers.
None of the 10 provided studies directly investigate the relationship between DHEA supplementation and hormone-sensitive cancers (e.g., breast or prostate cancer). The closest relevant study is PMID 36121077, a review on DHEA's pharmacological effects, but no key findings are reported in the provided data. While Attia's concern is biologically plausible given DHEA's role as a steroid precursor that can convert to androgens and estrogens, the available evidence base provided here does not contain studies that either confirm or refute a causal or associative link to hormone-sensitive cancers.
"supraphysiological levels can be androgenic."
Supraphysiological DHEA levels can be androgenic.
While the claim that supraphysiological DHEA levels can be androgenic is biologically plausible given DHEA's known role as a precursor to androgens like testosterone and DHT, none of the provided studies directly address or test this specific claim with extractable key findings. The most relevant studies (PMID 36121077 on DHEA pharmacology, PMID 16888459 on testosterone prohormone supplements, PMID 12943723 on androgens in women, and PMID 14644837 on androgens and antiandrogens) could theoretically contain supporting evidence, but no key findings are reported in the provided data to confirm this. Without extractable findings from these studies, a direct evidence-based comparison cannot be made.
"I do not recommend DHEA self-supplementation without testing and physician oversight."
Attia does not recommend DHEA self-supplementation without testing and physician oversight.
None of the 10 provided studies directly address the question of whether DHEA self-supplementation should require prior testing and physician oversight. The most relevant study (PMID: 36121077, a review of DHEA pharmacological effects) could theoretically speak to safety and dosing considerations, but no key findings or details were provided for any of the listed studies. The claim is a clinical caution recommendation rather than an empirical assertion, and the available evidence base as presented here cannot confirm or refute it.
"because it's a steroid precursor, there are theoretical concerns about hormone-sensitive cancers."
Because DHEA is a steroid precursor, there are theoretical concerns about hormone-sensitive cancers.
"I do not recommend DHEA self-supplementation without testing and physician oversight."
Attia does not recommend DHEA self-supplementation without testing and physician oversight.
"its conversion to sex steroids means it can raise estrogen in men and testosterone in women, which may not be desirable."
DHEA's conversion to sex steroids means it can raise estrogen in men and testosterone in women, which may not be desirable.
None of the 10 listed studies provide extractable findings (key findings, populations, and limitations are all listed as 'None') that directly test or confirm DHEA's conversion to estrogen in men or testosterone in women. While the claim is biologically plausible given DHEA's known role as a steroid precursor — and some listed reviews (e.g., PMID 36121077 on DHEA pharmacology, PMID 12943723 on androgens in women) may contain relevant content — no usable data from these sources can be evaluated as presented. Without accessible findings from the retrieved literature, a meaningful evidence-based assessment cannot be made.
"its conversion to sex steroids means it can raise estrogen in men and testosterone in women, which may not be desirable."
DHEA's conversion to sex steroids means it can raise estrogen in men and testosterone in women, which may not be desirable.
"supraphysiological levels can be androgenic."
Supraphysiological DHEA levels can be androgenic.